Search results
Showing 541 to 555 of 1559 results for do not do recommendations
Omalizumab for previously treated chronic spontaneous urticaria (TA339)
Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.
Cochlear implants for children and adults with severe to profound deafness (TA566)
Evidence-based recommendations on cochlear implants for children and adults with severe to profound deafness.
Preventing suicide in community and custodial settings (NG105)
This guideline covers ways to reduce suicide and help people bereaved or affected by suicides. It aims to:
Abaloparatide for treating osteoporosis after menopause (TA991)
Evidence-based recommendations on abaloparatide (Eladynos) for treating osteoporosis after menopause in women, trans men and non-binary people with a very high risk of fracture.
Spinal metastases and metastatic spinal cord compression (QS56)
This quality standard covers diagnosis and management of spinal metastases and metastatic spinal cord compression. It describes high-quality care in priority areas for improvement.
View quality statements for QS56Show all sections
Sections for QS56
- Quality statements
- Quality statement 1: Information about recognising the symptoms of metastatic spinal cord compression
- Quality statement 2: Imaging and treatment plans for adults with suspected spinal metastases
- Quality statement 3: Imaging for adults with suspected metastatic spinal cord compression
- Quality statement 4: Coordinating investigations for adults with suspected metastatic spinal cord compression
- Quality statement 5: Coordinating care for adults with metastatic spinal cord compression
- Quality statement 6: Radiotherapy for metastatic spinal cord compression
- Quality statement 7: Supportive care and rehabilitation
Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.
This guideline covers the general principles for managing intravenous (IV) fluid therapy in hospital inpatients aged 16 and over with a range of conditions. It aims to help prescribers understand the optimal amount and composition of IV fluids to be administered and the best rate at which to give them, to improve fluid prescribing and outcomes among people in hospital. It does not cover pregnant women, and those with severe liver or renal disease, diabetes or burns.
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (TA119)
Evidence-based recommendations on fludarabine monotherapy for untreated chronic lymphocytic leukaemia in adults.
This interim statement outlines early value assessments, a new evidence-based approach designed to improve the care of people and effective use of NHS resources through quicker access to promising health technologies that address national unmet need
This quality standard covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date, and babies born at term, up to 28 days after their birth. It describes high-quality care in priority areas for improvement.
Naltrexone–bupropion for managing overweight and obesity (TA494)
Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults.
This quality standard covers the prevention, diagnosis and management of delirium in adults (aged 18 and over) in hospital or long-term care settings (such as residential care or nursing homes). It describes high-quality care in priority areas for improvement.
View quality statements for QS63Show all sections
Sections for QS63
- Quality statements
- Quality statement 1: Assessing recent changes that may indicate delirium
- Quality statement 2: Interventions to prevent delirium
- Quality statement 3: Use of antipsychotic medication for people who are distressed
- Quality statement 4: Information and support
- Quality statement 5: Communication of diagnosis to GPs
- Update information
- About this quality standard
Evidence-based recommendations on brexucabtagene autoleucel (Tecartus) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over.
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)
Evidence-based recommendations on pralsetinib (Gavreto) for treating RET fusion-positive advanced non-small-cell lung cancer in adults.
High-throughput non-invasive prenatal testing for fetal RHD genotype (HTG420)
Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype.